BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1484 related articles for article (PubMed ID: 31071448)

  • 1. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing targeted DNA methylation and demethylation using dCas9.
    Pflueger C; Swain T; Lister R
    Essays Biochem; 2019 Dec; 63(6):813-825. PubMed ID: 31724704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active fusions of Cas9 orthologs.
    Josipović G; Zoldoš V; Vojta A
    J Biotechnol; 2019 Aug; 301():18-23. PubMed ID: 31158410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
    Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
    J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-based epigenome editing: mechanisms and applications.
    Fadul SM; Arshad A; Mehmood R
    Epigenomics; 2023 Nov; 15(21):1137-1155. PubMed ID: 37990877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
    Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
    Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
    Lau CH; Suh Y
    Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas mediated epigenome editing for cancer therapy.
    Ansari I; Chaturvedi A; Chitkara D; Singh S
    Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.
    Bae T; Hur JW; Kim D; Hur JK
    Genes Genomics; 2019 Aug; 41(8):871-877. PubMed ID: 31119685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review.
    Syding LA; Nickl P; Kasparek P; Sedlacek R
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notes on Functional Modules in the Assembly of CRISPR/Cas9-Mediated Epigenetic Modifiers.
    Kondrashov A; Karpova E
    Methods Mol Biol; 2021; 2198():401-428. PubMed ID: 32822047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing CRISPR-Cas9 for Epigenetic Engineering.
    Guerra-Resendez RS; Hilton IB
    Methods Mol Biol; 2022; 2518():237-251. PubMed ID: 35666449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Points of View on the Tools for Genome/Gene Editing.
    Chuang CK; Lin WM
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review on CRISPR/Cas-based epigenetic regulation in plants.
    Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
    Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
    Goubert D; Koncz M; Kiss A; Rots MG
    Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-Based Engineering of the Epigenome.
    Pulecio J; Verma N; Mejía-Ramírez E; Huangfu D; Raya A
    Cell Stem Cell; 2017 Oct; 21(4):431-447. PubMed ID: 28985525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CasKAS: direct profiling of genome-wide dCas9 and Cas9 specificity using ssDNA mapping.
    Marinov GK; Kim SH; Bagdatli ST; Higashino SI; Trevino AE; Tycko J; Wu T; Bintu L; Bassik MC; He C; Kundaje A; Greenleaf WJ
    Genome Biol; 2023 Apr; 24(1):85. PubMed ID: 37085898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing.
    Chen X; Chen Y; Xin H; Wan T; Ping Y
    Proc Natl Acad Sci U S A; 2020 Feb; 117(5):2395-2405. PubMed ID: 31941712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.
    Pei WD; Zhang Y; Yin TL; Yu Y
    Brief Funct Genomics; 2020 May; 19(3):215-228. PubMed ID: 31819946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy.
    Maroufi F; Maali A; Abdollahpour-Alitappeh M; Ahmadi MH; Azad M
    Epigenomics; 2020 Oct; 12(20):1845-1859. PubMed ID: 33185489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.